Combination therapies that include BCL2 inhibitors, such as venetoclax, paired with cytotoxic or hypomethylating agents, present a promising treatment strategy for NUP98‐r AML, despite the limited clinical data available for this subgroup. The gene discussed is NUP98; the disease is acute myeloid leukemia.